A New Hope For The Treatment Of Life-Threatening Acute-on-Chronic Liver Failure

Akaza Bioscience is a biopharmaceutical company pioneering the development of Resatorvid (TAK-242), a novel immunological therapy for the treatment of Acute-on-Chronic Liver Failure (ACLF).

ACLF Is A Rapidly Progressive, Life-Threatening Disease With No Specific, Effective Medical Treatment

Acute on chronic liver failure (ACLF) is a syndrome which is characterised by acute decompensation of chronic liver disease. Many ACLF patients are inherently vulnerable, as the most common underlying causes are alcoholic and chronic viral hepatitis. While global chronic viral hepatitis rates continue to rise, there is currently no specific medical treatment for ACLF. Consequently, ACLF is associated with organ failure and devastatingly high 28-day mortality rates between 25-75%. TAK-242 is an innovative, novel treatment option which aims to address unmet clinical need and improve short-term survival rates.

Clinical Trial

Akaza Bioscience is preparing to run a Phase II study of TAK-242, a novel immunological therapy. This pan-European study aims to investigate the safety and efficacy of TAK-242, as measured by changes in key biomarkers and 28-day survival rates. The trial will be a randomised, double-blind, placebo-controlled study in patients with Grade 1 or 2 ACLF.

Our Partners

Akaza Bioscience has partners who share our commitment to develop TAK-242 for the benefit of ACLF patients


Contact Us

Send us an email using the form and one of the team will be in touch with you soon.

Please enter your name.
Please enter a valid phone number.
Please enter a message.